These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [nab-Paclitaxel as new therapeutic option for pancreatic cancer]. Michl P Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574 [No Abstract] [Full Text] [Related]
7. A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling. Cowan RW; Maitra A; Rhim AD Gastroenterology; 2015 Dec; 149(7):1685-8. PubMed ID: 26526714 [No Abstract] [Full Text] [Related]
8. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Chauhan VP; Boucher Y; Ferrone CR; Roberge S; Martin JD; Stylianopoulos T; Bardeesy N; DePinho RA; Padera TP; Munn LL; Jain RK Cancer Cell; 2014 Jul; 26(1):14-5. PubMed ID: 25026209 [No Abstract] [Full Text] [Related]
9. Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning. DelGiorno KE; Carlson MA; Osgood R; Provenzano PP; Brockenbough JS; Thompson CB; Shepard HM; Frost GI; Potter JD; Hingorani SR Cancer Cell; 2014 Jul; 26(1):16-7. PubMed ID: 25026210 [No Abstract] [Full Text] [Related]
10. Irreversible electroporation: a novel pancreatic cancer therapy. Weiss MJ; Wolfgang CL Curr Probl Cancer; 2013; 37(5):262-5. PubMed ID: 24331180 [No Abstract] [Full Text] [Related]
11. The case for a stratified application of targeted agents against pancreatic cancer. Bijlsma MF EBioMedicine; 2021 May; 67():103344. PubMed ID: 33910122 [No Abstract] [Full Text] [Related]
12. Harnessing immune responses in the tumor microenvironment: all signals needed. Le DT; Jaffee EM Clin Cancer Res; 2013 Nov; 19(22):6061-3. PubMed ID: 24097857 [TBL] [Abstract][Full Text] [Related]
13. Use of a preclinical model of pancreas cancer to identify potential candidates for rapalogue therapy. Takeuchi KK; Crawford HC Gut; 2014 Sep; 63(9):1379-80. PubMed ID: 24966285 [No Abstract] [Full Text] [Related]
14. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038 [TBL] [Abstract][Full Text] [Related]
15. [Pancreatic cancer: a major challenge in oncology]. Fölsch UR; Schäfer H Med Klin (Munich); 2004 Apr; 99(4):183-4. PubMed ID: 15085287 [No Abstract] [Full Text] [Related]
16. Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms. Lipkin S; Lee J; Imagawa D; Hewitt SM; Tucker C; Zell JA; Wong V; Garcia A; Gonzalez R; Della Zanna G; Richmond E; Rodriguez LM; Bigg M; Schnoll-Sussmans F; Meyskens F Cancer Prev Res (Phila); 2011 Apr; 4(4):512-3. PubMed ID: 21464031 [TBL] [Abstract][Full Text] [Related]